TY - JOUR
T1 - Cationic peptides
T2 - Effectors in innate immunity and novel antimicrobials
AU - Hancock, Robert Ew
N1 - Funding Information:
I thank the Canadian Bacterial Diseases Network and the Canadian and US Cystic Fibrosis Foundations for funding my own research on cationic peptides. I am the recipient of a Canada Research Chair in Microbiology. I thank Annett Rozek for drawing Figure 1 and Monisha Scott for her assistance in drawing Figure 5 .
PY - 2001/10/1
Y1 - 2001/10/1
N2 - Cationic antimicrobial peptides are produced by all organisms, from plants and insects to human beings, as a major part of their immediately effective, non-specific defences against infections. With the increasing development of antibiotic resistance among key bacterial pathogens, there is an urgent need to discover novel classes of antibiotics. Therefore, cationic peptides are being developed through clinical trials as anti-infective agents. In addition to their ability to kill microbes, these peptides seem to have effector functions in innate immunity and can upregulate the expression of multiple genes in eukaryotic cells. One such function might involve the dampening of signalling by bacterial molecules such as lipopolysaccharide and lipoteichoic acid.
AB - Cationic antimicrobial peptides are produced by all organisms, from plants and insects to human beings, as a major part of their immediately effective, non-specific defences against infections. With the increasing development of antibiotic resistance among key bacterial pathogens, there is an urgent need to discover novel classes of antibiotics. Therefore, cationic peptides are being developed through clinical trials as anti-infective agents. In addition to their ability to kill microbes, these peptides seem to have effector functions in innate immunity and can upregulate the expression of multiple genes in eukaryotic cells. One such function might involve the dampening of signalling by bacterial molecules such as lipopolysaccharide and lipoteichoic acid.
UR - https://www.scopus.com/pages/publications/0035496012
U2 - 10.1016/S1473-3099(01)00092-5
DO - 10.1016/S1473-3099(01)00092-5
M3 - Review article
C2 - 11871492
AN - SCOPUS:0035496012
SN - 1473-3099
VL - 1
SP - 156
EP - 164
JO - Lancet Infectious Diseases
JF - Lancet Infectious Diseases
IS - 3
ER -